Bluebird prices gene therapy at 1.575 million euros over five years
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.
from Reuters: Health News https://reut.rs/2RgciEG
http://bit.ly/2zwRqiM